Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma-Reference-Cited by-同舟云学术

Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma

Published:2018-04 Issue:4 Volume:73 Page:628-634
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Sarfaty Michal^ORCID,Leshno Moshe,Gordon Noa,Moore Assaf,Neiman Victoria,Rosenbaum Eli,Goldstein Daniel A.

Publisher

Elsevier BV

Subject

Urology

Reference30 articles.

1. Renal cell carcinoma;Curti;JAMA,2004

2. National Cancer Institute. SEER cancer statistics factsheets: kidney and renal pelvis cancer. https://seer.cancer.gov/statfacts/html/kidrp.html

3. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: kidney cancer. www.nccn.org/professionals/physician_gls/pdf/kidney.pdf

4. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial;Motzer;Lancet,2008

5. Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: role in advanced cancers;Rajan;Hum Vaccin Immunother,2016

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness of first-line enfortumab vedotin in addition to pembrolizumab for metastatic urothelial carcinoma in the United States;Frontiers in Immunology;2024-09-09

2. Scoping review of economic analyses of rare kidney diseases;Kidney International Reports;2024-09

3. Economic value of toripalimab plus axitinib as first-line treatment for advanced renal cell carcinoma in China: a model-based cost-effectiveness analysis;Expert Review of Pharmacoeconomics & Outcomes Research;2024-03-21

4. Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab Combination Therapy as First-line Treatment for Advanced Renal Cell Carcinoma in Japan;Value in Health Regional Issues;2024-03

5. Cost-Effectiveness of Treatment Optimisation with Biomarkers for Immunotherapy in Solid Tumours: A Systematic Review;Cancers;2024-02-29